Natural Killer Cells Play Role in Ability of CML Patients to Discontinue TKIs
Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Lymphoma